Therefore, although preclinical studies have shown that targeting PD-1/PD-L1 immune checkpoints attenuates pulmonary fibrosis, more evidence is needed to support how these preclinical studies can be transferred to practical clinical applications. Here, CD274 is linked to pulmonary fibrosis.